FDA
-
-
-
-
-
-
-
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX
-
-
-
-
-
-
-
AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH
-
-
-
-
-
-
-
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
-
-
-
-
-
-
-
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
-
-
-
-
-
-
-
Pre-Open Stock Movers 10/08: (CCXI) (SNDL) (MNTV) Higher; (ALLO) (AGRX) (CDTX) Lower (more...)
-
-
-
-
-
-
-
ChemoCentryx (CCXI) Announces Approval of TAVNEOS in Japan for Treatment of ANCA-Associated Vasculitis
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

